Journal ArticleDOI
Influence of Amino Acid Mutations and Small Molecules on Targeted Inhibition of Proteins Involved in Cancer.
Vishnupriya Kanakaveti,P. Anoosha,Ramasamy Sakthivel,Suresh K. Rayala,M. Michael Gromiha,M. Michael Gromiha +5 more
Reads0
Chats0
TLDR
Understanding and bridging mutations and altered PPIs will provide insights into the alarming signals leading to massive malfunctioning of a biological system in various diseases.Abstract:
Background Protein-protein interactions (PPIs) are of crucial importance in regulating the biological processes of cells both in normal and diseased conditions. Significant progress has been made in targeting PPIs using small molecules and achieved promising results. However, PPI drug discovery should be further accelerated with better understanding of chemical space along with various functional aspects. Objective In this review, we focus on the advancements in computational research for targeted inhibition of protein-protein interactions involved in cancer. Methods Here, we mainly focused on two aspects: (i) understanding the key roles of amino acid mutations in epidermal growth factor receptor (EGFR) as well as mutation-specific inhibitors and (ii) design of small molecule inhibitors for Bcl-2 to disrupt PPIs. Results The paradigm of PPI inhibition to date reflect the certainty that inclination towards novel and versatile strategies enormously dictate the success of PPI inhibition. As the chemical space highly differs from the normal drug like compounds the lead optimization process has to be given the utmost priority to ensure the clinical success. Here, we provided a broader perspective on effect of mutations in oncogene EGFR connected to Bcl-2 PPIs and focused on the potential challenges. Conclusion Understanding and bridging mutations and altered PPIs will provide insights into the alarming signals leading to massive malfunctioning of a biological system in various diseases. Finding rational elucidations from a pharmaceutical stand point will presumably broaden the horizons in future.read more
Citations
More filters
Journal ArticleDOI
Current progress and future perspectives of polypharmacology : From the view of non-small cell lung cancer
TL;DR: Drug repositioning introduces an affordable and efficient strategy to discover novel drug action, especially when integrated with recent systems biology driven stratagem, in combination with conventional anticancer agents to combat drug resistance in the near future.
Journal ArticleDOI
Forging New Scaffolds from Old: Combining Scaffold Hopping and Hierarchical Virtual Screening for Identifying Novel Bcl-2 Inhibitors.
TL;DR: A novel attempt in terms of blending scaffold hopping and hierarchical virtual screening in order to assess the hybrid method for its efficacy in identifying active lead molecules for emerging PPI target Bcl-2 (B-cell Lymphoma 2).
References
More filters
Journal ArticleDOI
Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia.
Dale L. Bixby,Moshe Talpaz +1 more
TL;DR: Understanding the pathogenesis of tyrosine kinase inhibitor resistance and the molecular rationale for the development of second and now third generation therapies for patients with CML will be keys to further disease control over the next 10 years.
Journal ArticleDOI
Structural biology and bioinformatics in drug design : opportunities and challenges for target identification and lead discovery
Tom L. Blundell,Bancinyane L. Sibanda,Rinaldo W. Montalvao,Suzanne C Brewerton,Vijayalakshmi Chelliah,Catherine L. Worth,Nicholas J. Harmer,Owen R. Davies,David F. Burke +8 more
TL;DR: Structural biology and bioinformatics have assisted in lead optimization and target identification where they have well established roles; they can now contribute to lead discovery, exploiting high-throughput methods of structure determination that provide powerful approaches to screening of fragment binding.
Journal ArticleDOI
Structure-based design of novel inhibitors of the MDM2-p53 interaction
Yosup Rew,Daqing Sun,Felix Gonzalez-Lopez de Turiso,Michael D. Bartberger,Hilary Plake Beck,Jude Canon,Ada Chen,David Chow,Jeffrey Deignan,Brian M. Fox,Darin J. Gustin,Xin Huang,Min Jiang,Xianyun Jiao,Lixia Jin,Frank Kayser,David J. Kopecky,Yihong Li,Mei-Chu Lo,Alexander M. Long,Klaus Michelsen,Jonathan D. Oliner,Tao Osgood,Mark L. Ragains,Anne Y. Saiki,Steve Schneider,Maria M. Toteva,Peter Yakowec,Xuelei Yan,Qiuping Ye,Dongyin Yu,Xiaoning Zhao,Jing Zhou,Julio C. Medina,Steven H. Olson +34 more
TL;DR: Optimization afforded AM-8553, a potent and selective MDM2 inhibitor with excellent pharmacokinetic properties and in vivo efficacy, and the discovery of novel inhibitors of theMDM2-p53 protein-protein interaction.
Journal ArticleDOI
Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein interaction.
John G. Allen,Matthew P. Bourbeau,G. Erich Wohlhieter,Michael D. Bartberger,Klaus Michelsen,Randall W. Hungate,Robert C. Gadwood,Rick D Gaston,Bruce Evans,Larry W Mann,Michael E Matison,Stephen Schneider,Xin Huang,Dongyin Yu,Paul S. Andrews,Andreas Reichelt,Alexander M. Long,Peter Yakowec,Evelyn Yang,Tani Ann Lee,Jonathan D. Oliner +20 more
TL;DR: A high-throughput screening effort identified 6,7-bis(4-bromophenyl)-7,12-dihydro-6H-chromeno[4,3-d][1,2,4]triazolo[1,5-a]pyrimidine as a potent inhibitor of the MDM2-p53 protein-protein interaction and co-crystallization with the target protein helped to direct further optimization and provided a tractable lead series
Journal ArticleDOI
Somatic mutations of epidermal growth factor receptor in colorectal carcinoma
Hisashi Nagahara,Koshi Mimori,Mitsuhiko Ohta,Tohru Utsunomiya,Hiroshi Inoue,Graham F. Barnard,Masaichi Ohira,Kosei Hirakawa,Masaki Mori +8 more
TL;DR: It is suggested that a distinct minority of colorectal adenocarcinomas exhibit somatic mutations of EGFR, and these tumors may be susceptible to gefitinib treatment.